Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Keros Therapeutics Q3 EPS $(1.33) Beats $(1.35) Estimate; Cash And Cash Equivalents Of $287.9M Is Expected To Fund Its Operating Expenses And Capital Expenditure Requirements Into Q4 Of 2025

Author: Benzinga Newsdesk | November 06, 2023 09:10am
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.33) per share which beat the analyst consensus estimate of $(1.35) by 1.48 percent. This is a 44.57 percent decrease over losses of $(0.92) per share from the same period last year.

Posted In: KROS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist